Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on developing peptides that inhibit MARCKS to treat patients with inflammatory diseases, today announced that data from pre-clinical studies of the Company’s proprietary peptides will be presented on Thursday, May 6, 2021 during the 2021 ARVO (Association for Research in Vision and Ophthalmology) Annual Meeting, May 1 – 7, 2021.
- Presentation Type: Paper Session
- Presentation Title: Peptide Inhibitors of MARCKS Reverse Endotoxin Induced Uveitis in Rats
- Session Title: Cytokines, growth factors, anti-inflammatory
- Session Date and Time: May 6, 2021 from 11:15 AM to 12:45 PM EDT
The presentation will be available to attendees when the Annual Meeting Virtual Platform launches on Saturday, May 1, 2021 at 6:45am, and will remain available until the site closes on Wednesday, June 30, 2021. Biomarck plans to post the presentation to Biomarck’s website under the Publications, Presentations section at www.biomarck.com.
MARCKS inhibitor peptides were effective in reducing the clinical severity of ocular inflammation and cellular influx in the EIU rat model of acute uveitis. These results indicate that MARCKS could be an effective therapeutic target to treat uveitis.
Dr Brian Gilger, DVM, MS, Dipl. ACVO, Dipl. ABT, Professor of Ophthalmology at North Carolina State University College of Veterinary Medicine, and lead investigator in the study, commented, “Since patients with uveitis have limited treatment options, these data are encouraging. Using Optical Coherence Tomography, we saw dramatic reductions in anterior chamber cell counts following treatment with peptides that inhibit MARCKS.”
Biomarck Pharmaceuticals, Ltd., is a clinical stage biotechnology company focused on treating patients with inflammatory and immunological diseases, using our platform of patent-protected peptides that have been developed to inhibit MARCKS. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. Inhibiting MARCKS with our peptides reduces the adverse effects of inflammation, including acute respiratory distress syndrome (ARDS) and cytokine storm. Phase 2 trials have been completed with our lead peptide, BIO-11006, in ARDS, COPD and NSCLC, confirming safety and efficacy in these three potential indications. In vivo data demonstrate that BIO-11006 and other peptides in the Biomarck pipeline inhibit inflammation in dermatology and ophthalmology models. Potential indications include uveitis, dry eye, atopic dermatitis and psoriasis.
This press release may contain forward-looking statements. Forward-looking statements are not guarantees, and they involve risks, uncertainties, and assumptions. The information in the press release should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.